Сравнение эффективности лосартана и комбинации валсартана / сакубитрила у лиц с хронической сердечной недостаточностью с низкой фракцией выброса левого желудочка в сочетании с сахарным диабетом 2 типа

Abstract

The purpose — to compare the efficacy and safety of the use of two regimens for the use of renin-angiotensin system blockers — valsartan / sacubitril (V/C) and losartan in patients with diabetes mellitus (DM) type 2 in combination with chronic heart failure (HF) and low ejection fraction (EF) of the left ventricle (LV). Material and methods. We observed 46 patients with type 2 diabetes. All these patients had previously suffered from myocardial infarction and had clinical manifestations of chronic HF class II-III with LV EF < 40%. All patients were recommended lifestyle changes, they received adequate hypoglycemic and organ-protective therapy. Two groups were distinguished: group A (16 patients, taking V/C at an initial dose of 100 mg/day, followed by titration to 400 mg/day) and group B (30 patients, taking losartan at an initial dose of 50 mg/day, with titration up to 150 mg/day). In the course of treatment and after 11 months, clinical and laboratory studies were performed, in dynamics, echocardiography with tissue Doppler, ultrasound of the brachiocephalic arteries, and a test with reactive hyperemia were performed. Results. During treatment in group A, compared with group B, a more significant positive dynamics of clinical manifestations and the following studied parameters were noted: HOMA-IR and ΔHOMA-B indices, glycated hemoglobin levels, chronic HF class, LV EF, left atrial volume index, ratio of early diastolic velocity of transmitral blood flow to early diastolic velocity of the mitral valve ring, carotid intima-media complex thickness, and indexbrachial arteries resistivity; all changes are significant. Conclusions. Combined neurohumoral blockade using V/S compared with losartan in patients with DM type 2 and chronic HF with low LV EF helped to have more positive changes in clinical-laboratory and instrumental indicators.